生物技术公司MoonLake Immunotherapeutics宣布,其创新药物Sonelokimab针对中轴型脊柱关节炎的二期临床试验取得积极顶线结果。该试验数据显示,Sonelokimab在主要疗效终点上表现出显著优势,为患者提供了新的治疗希望。
同时,公司披露了2025年度财务报告,核心财务指标稳健,研发投入持续加大,为后续临床推进提供资金保障。此次成果标志着MoonLake在免疫疗法领域取得重要突破。
生物技术公司MoonLake Immunotherapeutics宣布,其创新药物Sonelokimab针对中轴型脊柱关节炎的二期临床试验取得积极顶线结果。该试验数据显示,Sonelokimab在主要疗效终点上表现出显著优势,为患者提供了新的治疗希望。
同时,公司披露了2025年度财务报告,核心财务指标稳健,研发投入持续加大,为后续临床推进提供资金保障。此次成果标志着MoonLake在免疫疗法领域取得重要突破。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.